PT141 (Bremelanotide, CAS: 189691-06-3) is a synthetic cyclic heptapeptide, a modified analog of α-melanocyte-stimulating hormone (α-MSH) and a potent agonist of melanocortin receptors (MC1, MC3, MC4, MC5). Unlike traditional peptides, it bypasses the blood-brain barrier to directly target peripheral and central melanocortin receptors, making it a key research peptide for studying skin pigmentation, intimate wellness, and related neurophysiological pathways. Its lyophilized formulation ensures long-term stability and consistent potency for laboratory use.
Core Research Benefits
• Melanocortin Receptor Activation: Targets MC1 (skin) and MC4 (central nervous system) receptors for research on receptor-mediated physiological responses.
• Skin Pigmentation Regulation: Stimulates melanin production in melanocytes, a key research focus for tanning and skin pigmentation studies.
• Intimate Wellness Research: A primary research peptide for studying melanocortin-related pathways in female and male intimate physiological function.
• Stable Physiological Activity: Synthetic cyclic structure enhances bioactivity and resistance to enzymatic degradation, ideal for in vitro and in vivo research.
• Broad Receptor Targeting: Acts on multiple melanocortin receptors, enabling research on diverse physiological and cellular responses.
